GT Biopharma Inc logo

GT Biopharma Inc(GTBP)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$3.72
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for GTBP

11/13/2026: GTBP (1-star) is currently NOT-A-BUY. Pass it for now.

GT Biopharma Inc is a clinical-stage biotechnology stock focused on developing targeted immuno-oncology therapies using its proprietary TriKE natural killer cell engager platform. The company's primary operational strengths lie in advancing pipeline candidates like GTB-3650 and GTB-5550 through early clinical trials. Its main investment story centers on the potential of its proprietary technology to unlock lucrative partnership or acquisition opportunities in cancer treatment. However, the company faces substantial execution, funding, and dilution risks due to its early pre-revenue status and tight cash runway. This stock suits speculative growth investors comfortable with high volatility, while key developments to monitor include ongoing clinical trial data readouts and capital-raising updates.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitThe company lacks commercial revenue growth, making it a speculative clinical-stage bet rather than an established growth stock.
Momentum investorStrong fit while signal remains positiveLow-float clinical biotechs can experience sharp short-term momentum spikes around clinical trial catalysts or regulatory updates.
Value investorWeak fitTraditional fundamental valuation metrics are inapplicable due to recurring operational losses and absence of earnings.
Dividend investorWeak fitThe company pays no dividends and reinvests all capital into survival and clinical testing.
Low-risk investorWeak fitHigh clinical uncertainty, volatility, and capital dilution risks make this unsuitable for conservative investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighLow market capitalization and clinical dependency cause sharp price swings.
Valuation riskHighStock pricing is driven by sentiment and trial expectations rather than traditional cash flow metrics.
Competition risk (biotech/immuno-oncology competition)HighWell-funded peers could outpace GT Biopharma's therapeutic candidates.
Business qualityMedium / highThe science relies on innovative platform technology, but early-stage corporate viability remains unproven.
Dividend incomeLow / noneNo cash distribution is available or planned for equity holders.
Execution riskHighClinical trial success, patient recruitment, and regulatory clearances are mandatory for survival.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 7.67M USD
Price to earnings Ratio -
1Y Target Price 75
Price to earnings Ratio -
1Y Target Price 75
Volume (30-day avg) 63.0K shares
Beta 0.83
52 Weeks Range 3.60 - 23.60
Updated Date 11/15/2026
52 Weeks Range 3.60 - 23.60
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -147.5

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -60.76%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
GTBP receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
GTBP has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-115.4%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
GTBP's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
GTBP's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-115.4%, negative) and free-cash-flow growth (-0.1%, slightly negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 7.4% and approximately 75.0% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 10.54% supports management-shareholder alignment.

Top 5 Institutional Investors

Vanguard Capital Management, LLC 0.73%
Geode Capital Management, LLC 0.52%
Vanguard Fiduciary Trust Co 0.44%
HRT FINANCIAL LLC 0.21%
Everhart Financial Group, Inc. 0.19%

Unit Economics (Per $1K Revenue)

★★★★★
GTBP generates approximately $0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
GTBP has a liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Small / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Therapeutic Licensing and Commercialization (Prospective)Future revenue from drug commercialization, milestone payments, or co-development partnerships derived from the TriKE platform.The company currently does not make meaningful money from product sales and depends on capital raises and future partnering deals.

Valuation

Trailing PE -
Forward PE 17.33
Enterprise Value 1.75M
Price to Sales(TTM) 204.96
Enterprise Value 1.75M
Price to Sales(TTM) 204.96
Enterprise Value to Revenue 773.27
Enterprise Value to EBITDA -0.09
Shares Outstanding 2.06M
Shares Floating 1.55M
Shares Outstanding 2.06M
Shares Floating 1.55M
Percent Insiders 10.54
Percent Institutions 7.4

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.